VBI Vaccines Presents Phase 3 Sci-B-Vac Data at ID Week 2020 - Seite 2

Nachrichtenquelle: Business Wire (engl.)
26.10.2020, 13:00  |  148   |   |   

Title: Rapid onset of seroprotection rates in young adults immunized with a 3-antigen hepatitis B virus (HBV) vaccine compared to a single-antigen HBV vaccine

During the presentation, Timo Vesikari M.D., Ph.D., Professor Emeritus and Director of the Nordic Vaccine Research Network in Finland, and principal investigator of the PROTECT and CONSTANT Phase 3 clinical studies discussed the kinetics of seroprotection offered by Sci-B-Vac vs. Engerix-B in adults age 18-45, as demonstrated in five late-stage studies completed to-date: four Phase 3 studies, including PROTECT, CONSTANT, 38-13-040, SG-005-05; and one Phase 4 study, SCIB018.

“In the U.S., we are seeing elevated rates of new hepatitis B infections in younger adults, particularly those aged 30-39,” said Dr. Vesikari. “In these studies, we analyzed the seroprotection levels induced after two and three doses of vaccine, which demonstrated that Sci-B-Vac was able to more rapidly induce high rates of seroprotection than Engerix-B, with differences in speed to seroprotection notably distinct in the larger registrational studies, PROTECT and CONSTANT. This may be particularly relevant for adults age 18-45 who may require faster onset of protection against HBV.”

The e-poster data included:

  • Faster onset of seroprotection in adults age 18-45 – seroprotection rate (SPR) is defined as the percent of subjects with anti-HBs titers ≥ 10 mIU/mL:
    • In the four controlled Phase 3 studies, after two vaccinations, Sci-B-Vac achieved SPR rates of 87.2%-100% compared to 39.0%-89.4% for Engerix-B
    • In the uncontrolled Phase 4 study, Sci-B-Vac achieved a 91.9% SPR at month 2, growing to 98.8% prior to receiving the third vaccination at month 6

Copies of both e-posters are available on the “Events/Presentations” page in the “Investors” section of VBI’s website.

About VBI Vaccines Inc.

VBI Vaccines Inc. (Nasdaq: VBIV) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology. VBI is advancing the prevention and treatment of hepatitis B, with: (1) the only 3-antigen hepatitis B vaccine, Sci-B-Vac, which is approved for use and commercially available in Israel and recently completed its Phase 3 program in the U.S., Europe, and Canada; and (2) an immunotherapeutic in development for a functional cure for chronic hepatitis B. VBI’s enveloped virus-like particle (eVLP) platform technology enables development of eVLPs that closely mimic the target virus to elicit a potent immune response. VBI’s lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program. VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel. Website Home: http://www.vbivaccines.com/ News and Insights: http://www.vbivaccines.com/wire/ Investors: http://www.vbivaccines.com/investors/

Seite 2 von 4
VBI Vaccines Aktie jetzt über den Testsieger (Finanztest 11/2020) handeln, ab 0 € auf Smartbroker.de

Diesen Artikel teilen

0 Kommentare

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren



VBI Vaccines Presents Phase 3 Sci-B-Vac Data at ID Week 2020 - Seite 2 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today announced the presentation of two abstracts featuring data from the Phase 3 …

Nachrichten des Autors